HMG CoA-reductase inhibitors or statins are clearly the most effective class of drugs for lowering LDL cholesterol. Those drugs have been associated with a beneficial impact on cardiovascular morbidity and mortality.
The appearance of angiotensin receptor blockers (ARBs) amongst the therapeutic options in the treatment of cardiovascular diseases (CVDs) was a new milestone in the history of hypertension treatment. It further widened the range of possibilities for personalized therapy, especially for patients who cannot tolerate the use of angiotensin converting enzyme inhibitors (ACEIs). Continue reading